New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
14:50 EDTNEON, IDRA, OUTR, PHHHigh option volume stocks: IDRA PHH VI NEON OUTR
News For IDRA;PHH;OUTR;NEON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
08:52 EDTIDRAIdera Pharmaceuticals provides development update on IMO-9200
Idera Pharmaceuticals announced the achievement of key development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors, or TLRs, 7, 8 and 9. Specifically, the company reported top-line data from a Phase 1 clinical trial of IMO-9200 in healthy subjects and announced the presentation of new preclinical data for IMO-9200 in models of inflammatory bowel disease, or IBD, at the 2015 Digestive Disease Week Conference, or DDW, in Washington, DC. In the placebo-controlled Phase 1 clinical trial in 30 healthy subjects, IMO-9200 was administered by subcutaneous injection at escalating single-dose levels of 0.1, 0.3, and 0.5 mg/kg. In the multiple dose cohort, a dose of 0.5 mg/kg/week for four weeks was also evaluated. All dose regimens were well tolerated, with no serious adverse events related to IMO-9200 treatment reported. There were no patterns of laboratory or other safety parameters suggestive of any related adverse treatment effect. Additionally, new preclinical data for IMO-9200 were presented on Saturday, May 16 at the 2015 Digestive Disease Week Conference. The poster presentation, entitled "Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Activity of Oral IMO-9200, an Antagonist of TLRs 7, 8, and 9 in Mouse Models of Colitis," provided results from two mouse models of colitis. These results demonstrated the potential of orally dosed IMO-9200 as a treatment for inflammatory bowel disease, which includes Crohn's disease, or CD, and ulcerative colitis.
May 13, 2015
09:32 EDTPHHPHH Corp. management to meet with FBR Capital
Subscribe for More Information
May 11, 2015
10:46 EDTNEONNeonode management to meet with Craig Hallum
Meetings to be held in New York on May 12 and in Boston on May 13 hosted by Craig Hallum.
09:59 EDTOUTROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:38 EDTIDRAIdera Pharmaceuticals reports Q1 EPS (12c), consensus (11c)
Subscribe for More Information
07:04 EDTOUTROuterwall removed from Focus List as a sell at JPMorgan
JPMorgan removed Outerwall from its Analyst Focus List as a sell, saying Redbox price increases should provide revenue support over the near term. The firm still expects DVD declines to accelerate in the second half of 2015 and keeps an Underweight rating on the stock with a $58 price target.
06:39 EDTOUTROuterwall downgraded to Equal-Weight from Overweight at First Analysis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use